Infant Bacterial Therapeutics Logo

Infant Bacterial Therapeutics

ISIN: SE0008015259 | Ticker: IBT | LEI: 2138008KVBXCRJGP6Z26
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Sweden

About Infant Bacterial Therapeutics

Company Description

IBT is a pharmaceutical company with its registered office in Stockholm with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants.

IBT is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Year founded



Bryggargatan 10, 11121 Stockholm – Sweden

Filings & Publications

Sign up and we will give you access!

Insider Trades

Date Trading entity / Person Association Trade type Volume
09.06.23 Maria Ekdahl Other Buy SEK 49,956.00
23.05.23 Anders Kronström Other Buy SEK 56,482.50
23.05.23 Anthon Jahreskog Other Buy SEK 36,593.00
23.05.23 Maria Ekdahl Other Buy SEK 19,995.00
23.05.23 Anthon Jahreskog Other Buy SEK 6,377.20
23.05.23 Anthon Jahreskog Other Buy SEK 6,269.92
22.05.23 Maria Ekdahl Other Buy SEK 30,487.00
20.05.23 Anders Kronström Other Buy SEK 82,250.00
21.11.22 Maria Ekdahl Other Buy SEK 15,800.00
30.05.22 Staffan Strömberg Other Buy SEK 840,000.00

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.